Abstract
The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.
| Original language | English (US) |
|---|---|
| Article number | 673 |
| Journal | Nature Communications |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 1 2018 |
Fingerprint
ASJC Scopus subject areas
- Chemistry(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Physics and Astronomy(all)
Cite this
Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone. / Li, Xiao Feng; Dong, Hao Long; Wang, Hong Jiang; Huang, Xing Yao; Qiu, Ye Feng; Ji, Xue; Ye, Qing; Li, Chunfeng; Liu, Yang; Deng, Yong Qiang; Jiang, Tao; Cheng, Gong; Zhang, Fu Chun; Davidson, Andrew D.; Song, Ya Jun; Shi, Pei-Yong; Qin, Cheng Feng.
In: Nature Communications, Vol. 9, No. 1, 673, 01.12.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone
AU - Li, Xiao Feng
AU - Dong, Hao Long
AU - Wang, Hong Jiang
AU - Huang, Xing Yao
AU - Qiu, Ye Feng
AU - Ji, Xue
AU - Ye, Qing
AU - Li, Chunfeng
AU - Liu, Yang
AU - Deng, Yong Qiang
AU - Jiang, Tao
AU - Cheng, Gong
AU - Zhang, Fu Chun
AU - Davidson, Andrew D.
AU - Song, Ya Jun
AU - Shi, Pei-Yong
AU - Qin, Cheng Feng
PY - 2018/12/1
Y1 - 2018/12/1
N2 - The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.
AB - The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.
UR - http://www.scopus.com/inward/record.url?scp=85042071353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042071353&partnerID=8YFLogxK
U2 - 10.1038/s41467-018-02975-w
DO - 10.1038/s41467-018-02975-w
M3 - Article
VL - 9
JO - Nature Communications
JF - Nature Communications
SN - 2041-1723
IS - 1
M1 - 673
ER -